【摘要】 目的针对塞瑞替尼与阿来替尼作为一线靶向药治疗中国ALK阳性的晚期非小细胞肺癌(NSCLC)患者,进行成本效用分析。方法运用Markov模型,模拟使用塞瑞替尼与阿来替尼的患者终身的医疗成本和质量调整生命年(QALY)。临床数据来源于多中心随机对照Ⅲ期临床试验数据,成本和效用值来自国家医保谈判价格和相关文献。敏感性分析包括单因素敏感性分析和概率敏感性分析。结果相对于塞瑞替尼一线治疗组的患者(2.69QALYs和117.58万元),阿来替尼组患者(4.68QALYs和285.91万元)的QALY提高1.99QALYs,成本增加168.34万元,ICER为84.59万元/QALY。结论作为一线治疗方案,阿来替尼能够使患者的生存时间延长,但医疗成本也相应增加。根据世界卫生组织制定的三倍人均GDP的衡量标准,使用塞瑞替尼一线治疗更具有经济性。更多还原

【Abstract】 OBJECTIVE To analyze the cost-effectiveness of CeritinibversusAlectinib as first-line targeted drugs therapy for anaplastic lymphoma kinase(ALK)-positive advanced non-small cell lung cancer(NSCLC) in China.METHODS The Markov model was used to assess the cost and utility using Ceritinib or Alectinib over a 10-years period.Clinical data were collected from the randomised phase 3 trials.Cost and utility values were derived from local charges and literature.RESULTS Compared with patients who used Ceritinib as first-line treatment,patients in the Alectinib group yielded an additional 1.99 QALYs with an incremental cost of 168.34 million yuan,so the incremental cost-effectiveness ratio(ICER) was 84.59 million yuanper QALY.CONCLUSIONS As a first-line treatment regimen,Alectinib can extend the survival time of patients compared with Ceritinib,but the medical cost also increases accordingly.According to the World Health Organization’s three-percent GDP measurement,first-line treatment with Ceritinib is the most cost-effective.更多还原